SAMHSA’s 2025 NSDUH Reframe Leaves Fentanyl Data Gaps

The Substance Abuse and Mental Health Services Administration (SAMHSA) has released the 2025 National Survey on Drug Use and Health (NSDUH), reframed as a five-year trend report spanning 2021–2025.

According to reporting by Filter magazine, the survey reflects 60,447 completed interviews and projects that 69.8 million people—about 24 percent of those aged 12+—used at least one unregulated drug in the past year, including marijuana, hallucinogens, cocaine, methamphetamine, heroin, and “misuse” of prescription opioids, stimulants, and tranquilizers/sedatives. Source: Filter.

Critically, the 2025 report continues a design introduced in 2022 that keeps street fentanyl—labeled “illegally made fentanyl” (IMF)—outside the main opioid questions and after substance use disorder (SUD) items.

That placement means SUD and opioid use disorder (OUD) estimates do not capture disorders arising solely from IMF use, leaving decision-makers with an incomplete picture.

Key changes in the 2025 NSDUH

The report’s five-year lens can flatten meaningful movement visible in individual years.

Filter reports that SAMHSA’s five-year framing often characterizes categories as “no change” from 2021–2025, even when 2025 shows meaningful movement versus prior years.

For example, a cocaine graphic suggests 18–25 use decreased for several years, then rose in 2025, yet the five-year summary reads as a decrease for that age group with “no change” elsewhere—muting visible 2025 shifts in cocaine trends.

The same pattern appears in the broader section on “misuse” of central nervous system stimulants.

Street fentanyl questions remain siloed, and the “Illegally Made Fentanyl Use” section spans just four paragraphs of the 157-page report, despite fentanyl’s central role in today’s opioid landscape.

Scientific Evidence and Research Findings

Per Filter’s analysis, the 2025 NSDUH estimates IMF past-year use at 0.3 percent (768,000 people) among those aged 12+, up from an average of roughly 660,000 users (about 0.2 percent) across 2022–2024.

Yet a reader would not learn that increase from the standalone 2025 report; it states no change by year or demographic for street fentanyl without consulting supplementary materials or prior releases.

The survey’s taxonomy is consequential.

Respondents are not asked about IMF until after SUD questions, so the core SUD, drug use disorder, and OUD metrics “do not capture disorders arising solely from the use of IMF,” as the report itself notes via Filter’s citation.

NSDUH remains the most cited population survey for behavioral health and drug use statistics, but Filter underscores long-standing issues: awkward category boundaries, ambiguous phrasing, and exclusions.

Notably, NSDUH is not administered to people living outside or in their cars, or to those in jail or prison—the very populations disproportionately impacted by SUD.

The 2025 report includes whether people received treatment while in prison, jail, or juvenile detention, but not what kind of treatment.

Opioid treatment measures and terminology

Filter reports that respondents who ever used heroin or prescription pain relievers were asked about being prescribed medication for opioid use disorder (MOUD), with accurate listings of methadone, buprenorphine, and naltrexone formulations.

However, the report then states MOUD “do not include the use of medications that are prescribed to manage withdrawal symptoms,” a language choice that may confuse data interpretation and policy analysis around patient access and treatment statistics.

Safety Considerations and Side Effects

Data design has safety consequences.

By siloing IMF and excluding corresponding disorders from SUD and OUD tallies, the survey may understate opioid-related need, creating “side effects” for public health data users: misallocated resources, delayed harm reduction responses, and incomplete risk assessments.

The brief IMF section concedes the estimates are “almost certainly an underestimate of true IMF use,” according to Filter.

When combined with the five-year trend lens, small but important 2025 shifts risk being flattened into “no change,” complicating how to prioritize interventions for fentanyl.

Medical Applications and Patient Benefits

Clearer fentanyl-related surveillance can help planners assess access to medications for opioid use disorder.

Our take: Accurate surveillance underpins patient-centered care.

If OUD estimates do not reflect IMF-related disorders, systems may fall short on MOUD availability where it is most needed.

Clarity around methadone, buprenorphine, and naltrexone usage patterns helps planners assess capacity and remove barriers—but only when measures align with real-world fentanyl exposure.

For cannabis research and medical marijuana discussions, NSDUH shapes public narratives by listing marijuana among “unregulated drugs,” yet this same report shows how taxonomy choices can influence perceived risk and need.

That’s why precise survey methodology matters as much as raw counts.

For readers interested in cannabis science, see our education pieces on cannabis research basics and policy analysis in the DMV.

What this means for DC, Maryland and Virginia

DMV agencies, health systems, and community organizations often rely on federal agencies’ population survey data to plan services.

When NSDUH downplays IMF-related disorder and frames year-to-year bumps as “no change,” DMV stakeholders should use caution before treating 2025 signals as negligible.

Washington DC, Maryland, and Virginia have diverse urban and suburban settings where harm reduction needs can shift quickly.

Using multiple data inputs, asking “how to” interpret five-year trends, and stress-testing assumptions about stimulant misuse or fentanyl can improve local decisions.

For cannabis policy watchers, remember that NSDUH’s category grouping includes marijuana alongside other substances; interpretations should account for taxonomy limits before drawing conclusions about medical marijuana or broader cannabis research impacts.

What changed about the 2025 NSDUH?

Filter reports SAMHSA framed the release as a five-year trend (2021–2025) and continued to place illegally made fentanyl questions after SUD items, keeping IMF-related disorders out of the main SUD and OUD measures.

How is illegally made fentanyl (IMF) counted?

IMF is asked in a separate section, not integrated into the primary opioid items.

Filter notes 2025 past-year IMF use at 0.3 percent (768,000 people), up from about 0.2 percent in 2022–2024, though the 2025 report itself states no change across years without supplemental context.

Does the survey measure opioid use disorder from fentanyl?

As summarized by Filter, overall SUD, drug use disorder, and OUD measures do not include disorders arising solely from IMF because the questions appear after the SUD section.

This limits direct alignment of OUD metrics with real-world fentanyl exposure.

Why does the five-year trend framing matter?

It can blur meaningful year-specific changes.

Filter highlights examples like cocaine trends among ages 18–25 that appear to dip, then rise in 2025, while the report characterizes the period as a general decrease or “no change.”

Who is excluded from the survey?

NSDUH does not reach people living outside or in their cars, or those in jail or prison, per Filter’s reporting.

While it asks whether people received treatment while incarcerated or detained, it does not specify what kind of treatment.

Is marijuana included, and what does that mean for cannabis research?

Yes—per Filter, the NSDUH category of unregulated drugs includes marijuana.

That framing shapes public health narratives but, as the fentanyl example shows, taxonomy and placement can affect interpretations relevant to cannabis research and medical marijuana discourse.

Editorial notes and reader guidance

Our take: Treat 2025 figures as one input, not the sole guide.

Ask how category boundaries, question order, and excluded populations may shift results before drawing conclusions about policy analysis, treatment statistics, or patient access.

For DMV readers working in harm reduction or behavioral health, triangulate NSDUH with local public health data when planning services.

Resources for further medical consultation

This article is for education only and is not medical advice.

If you have questions about substance use, opioid use disorder, MOUD options like methadone, buprenorphine, or naltrexone, or cannabis in your care plan, speak with a licensed clinician.

For the full context on the 2025 report, read Filter’s original analysis: SAMHSA Reframes National Drug Use Survey, Leaves Fentanyl Problem Intact.

Takeaway: The 2025 report is influential, but its IMF silo and five-year lens can understate real-world risk.

DMV policymakers and clinicians should read carefully, validate assumptions, and plan with caution.

Source: Filter

---

Written by Culture Curator AI

Bud Lords AI Cannabis News Writer

Lifestyle and cultural voice covering events, strains, social aspects, and DMV cannabis culture. More casual, engaging tone.

Expertise: culture · lifestyle

View more from Culture Curator AI

This AI-assisted article was created using the named Bud Lords newsroom personality and reviewed under Bud Lords editorial standards.